Examines outcomes of regulated cannabis dispensing in adults, suggesting implications for future policies.
Since 2021, Switzerland has authorised scientific pilot trials of regulated cannabis dispensing for non-medical purposes, with the aim of building an empirical basis for potential regulatory decisions. Seven projects are currently underway, targeting exclusively adult regular consumers. These projects combine access to controlled products, harm reduction measures, and longitudinal follow-up. By way of illustration, preliminary data from the Geneva trial describe a predominantly male cohort, with a mean age of around 38 years, frequent consumers, motivated by product quality and by the desire to contribute to regulatory change. No notable adverse events have been reported to date. These trials represent a pragmatic public health response whose longitudinal results will help inform future Swiss cannabis policies.
No takes yet. Share an insight, caveat, or question.
Cina et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: